Standout Papers

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-lab... 2020 2026 2022 2024409
  1. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial (2020)
    Catherine A. Shu, Justin F. Gainor et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 54 standout
Sub-graph 1 of 22

Citing Papers

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy
2024 Standout
2 intermediate papers

Works of Mark Stoopler being referenced

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
2020 Standout

Author Peers

Author Last Decade Papers Cites
Mark Stoopler 830 702 157 177 17 1.1k
Ryoji Kato 697 1145 119 199 22 1.4k
A-P Meert 782 720 69 537 13 1.3k
Jeltje F. de Vries 646 722 77 117 15 1.2k
Shiyang Kang 855 1082 108 229 27 1.4k
Henry Xiong 297 758 236 341 20 1.1k
Hao Yu 556 755 160 262 26 1.1k
Sue-Hwa Lin 480 628 134 529 23 1.2k
Anita Midha 914 961 119 238 16 1.3k
Darrel P. Cohen 770 276 258 285 30 1.2k
Takamitsu Onitsuka 612 633 150 531 28 1.2k

All Works

Loading papers...

Rankless by CCL
2026